- 24/7 Wall St.•7 days ago
Medivation has been among the top future biotech mergers for quite some time. The problem is that we still have no idea which company will buy Medivation, nor do we know what price.
- Barrons.com•8 days ago
After surveying doctors on the preferred hepatitis-C treatments, Baird's Brian Skorney and Neena Bitritto-Garg contend that Gilead Sciences (GILD) is likely to maintain its dominance over AbbVie (ABBV), Merck (MRK) and Johnson & Johnson (JNJ) but in what appears to be a shrinking market. In conjunction with script trends, physicians indicate that the market for treatment-eligible, easily accessible Hep C patients is shrinking, but that Gilead's share of the shrinking pie is continuing to grow.
Merck KGaA (MKGAF)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||107.04 - 107.04|
|52wk Range||94.87 - 111.02|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||29.52|
|Avg Vol (3m)||2,145|
|Dividend & Yield||1.20 (1.10%)|